All In Biotech

Drug Trial Radar · NCT00527865

Single Dose Escalating Study of DAS181 in Adults

Study 181-1-06-01 - Phase 1A Clinical Study With DAS181: Double-Blind, Randomized, Placebo-Controlled, Single Dose Escalating Study in Healthy Adults

Last checked: Nov 19, 2026Latest source record: Jan 8, 2009 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

36

Planned (sponsor's estimate)

Start

Oct 2007

Primary completion

Dec 2008

Study completion Jan 2009

Sponsor

Lead sponsor
Ansun Biopharma, Inc.Industry
Sponsor type
Industry
Collaborators
National Institute of Allergy and Infectious Diseases (NIAID)
First posted
Sep 11, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Single group
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study will evaluate the safety, tolerability, and systemic exposure of an experimental influenza (flu) treatment medication called DAS181. DAS181 is a dry powder that is administered via oral inhalation using a special device. Study participants will include up to 60 healthy, non-smoking males and females, ages 18-65. They will be given either DAS181 or placebo. Participants will remain in the clinic overnight to be watched for health changes for 24 hours after receiving the medication. Study procedures include: physical exams, chest x-rays, ECGs, lung function tests, collection of blood and urine samples, and throat swabs. Follow-up visits will occur on study days 2, 7, 14 +/- 1 day, and 30 +/- 2 days. Participants will be involved in the study for up to 61 days, which includes the screening period.

Conditions

  • Influenza

Interventions

  • DAS181Drug

    DAS181 is formulated as dry powder and packaged in capsules containing DAS181. The delivered dose of DAS181 dry powder at each fill size is 0.5 mg, 1.0 mg, 2.25 mg, and 4.5 mg.

  • PlaceboDrug

    Capsules containing 10.5 mg of lactose will be supplied as placebo.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerability of a single-dose of DAS181 treatment at 0.5 mg, 1.0 mg, 2.25 mg, and 4.5 mg.Time frame: Duration of study

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Comprehensive Phase One

    Miramar, Florida

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.